7 July, 2008, London, UK: Cancer drug developer Antisoma plc (LSE:
ASM; USOTC: ATSMY) today announces that two Non-Executive Directors
of Antisoma have taken part of their fees for the quarter ended 30
June 2008 in ordinary shares pursuant to resolutions of the Board of
Directors dated 14 September 2004 and subsequently.
The new ordinary shares were issued at a price of 23.0 pence per
share, being the mid-market closing price on the last trading day of
the quarter (30 June 2008). The relevant Directors have agreed not to
dispose of the shares allotted to them for a minimum period of one
The allotments and total holdings following these allotments are
Director Allotted Total Percentage of
7 July 2008 holding ordinary shares
Michael Pappas 16,304 768,089 0.13%
Dale Boden 20,108 794,111* 0.13%
* Mr Boden's total holdings include a beneficial interest totalling
638,469 ordinary shares held by BF Capital, BFC III Ltd and by The
Sentinel I Trust.
Application will be made to the London Stock Exchange and the UK
Listing Authority for the admission of the new ordinary shares of 1p
each. The total number of ordinary shares in the Company in issue and
admitted to the Official List following the above allotments will be
The new ordinary shares will rank pari passu with the Company's
existing ordinary shares.
Daniel Elger, Director of Communications
+44 (0)20 3249 2100
Background on Antisoma
Antisoma is a London Stock Exchange-listed biopharmaceutical company
that develops novel products for the treatment of cancer. The Company
has operations in the UK and the US. Please visit www.antisoma.com
for further information about Antisoma.
---END OF MESSAGE---